Dihydroergotoxin Mesylate
Brand names,
Dihydroergotoxin Mesylate
Analogs
Dihydroergotoxin Mesylate
Brand Names Mixture
Dihydroergotoxin Mesylate
Chemical_Formula
C33H45N5O5
Dihydroergotoxin Mesylate
RX_link
No information avaliable
Dihydroergotoxin Mesylate
fda sheet
Dihydroergotoxin Mesylate
msds (material safety sheet)
Dihydroergotoxin Mesylate
Synthesis Reference
No information avaliable
Dihydroergotoxin Mesylate
Molecular Weight
591.741 g/mol
Dihydroergotoxin Mesylate
Melting Point
No information avaliable
Dihydroergotoxin Mesylate
H2O Solubility
No information avaliable
Dihydroergotoxin Mesylate
State
Solid
Dihydroergotoxin Mesylate
LogP
2.615
Dihydroergotoxin Mesylate
Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Dihydroergotoxin Mesylate
Indication
For use as an adjunct therapy for patients with dementia
Dihydroergotoxin Mesylate
Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Dihydroergotoxin Mesylate
Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Dihydroergotoxin Mesylate
side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Dihydroergotoxin Mesylate
Patient Information
No information avaliable
Dihydroergotoxin Mesylate
Organisms Affected
Humans and other mammals